Prospect: information for the user
Voriconazole Teva 200 mg powder for solution for infusion EFG
Read this prospect carefully before starting to take this medicine,because it contains important information for you.
- This medicine has been prescribedonlyto you, and you must not give it to other people althoughtheymay havethe same symptomsas you,as it may harm them.
-If you experience any adverse effects, consult your doctor, pharmacist or nurse, even if they are not listed in this prospect. See section 4.
1.Voriconazole Teva 200 mg powder for solution for infusion and its use
2.What you need to knowbeforestarting touse Voriconazole Teva 200 mg powder for solution for infusion
3.How to use Voriconazole Teva 200 mg powder for solution for infusion
4.Possible adverse effects
5Storage of Voriconazole Teva 200 mg powder for solution for infusion
6.Contents of the package and additional information
Voriconazol Teva contains the active ingredient voriconazol. Voriconazol is an antifungal medication. It acts by eliminating or preventing the growth of fungi that cause infections.
It is used to treat patients (adults and children 2 years of age or older) with:
Voriconazol is used in patients with serious fungal infections that may put their lives at risk.
Prevention of fungal infections in bone marrow transplant recipients at high risk.
This medication must be used only under medical supervision.
No useVoriconazol Teva
It is very important to inform your doctor, pharmacist, or nurse if you are taking or have recently taken other medications, including those purchased without a prescription, or herbal remedies.
Do not take the following medications during treatment with voriconazole:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take voriconazole if:
Your doctor should monitor your liver and kidney function by performing blood tests.
Avoid exposure to the sun and sunlight during treatment. It is essential to cover exposed areas and use a high-factor sunscreen, as you may experience increased skin sensitivity to UV rays from the sun. This may be exacerbated by the use of other medications that sensitize the skin to sunlight, such as methotrexate. These precautions also apply to children.
Inform your doctor immediately if you develop the following symptoms while being treated with voriconazole:
If you develop skin problems as described above, your doctor may refer you to a dermatologist, who may consider regular examinations. There is a small probability that you may develop skin cancer with long-term use of voriconazole.
If you develop signs of "adrenal insufficiency" where the adrenal glands do not produce sufficient amounts of certain steroid hormones, such as cortisol, which may cause symptoms such as: chronic or prolonged fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, inform your doctor.
If you develop signs of "Cushing's syndrome" where the body produces too much cortisol hormone, which may cause symptoms such as: weight gain, hump of fat between the shoulders, rounded face, darkening of the skin on the abdomen, thighs, breasts, and arms, fine skin, easy bruising, high blood sugar, excessive hair growth, or excessive sweating, inform your doctor.
Your doctor should monitor your liver and kidney function by performing blood tests.
Children and adolescents
Voriconazole should not be administered to children under 2 years old.
Use of Voriconazol Teva with other medications
Inform your doctor or pharmacist if you are taking/using or have taken/used or may need to take/use other medications, including those purchased without a prescription.
Some medications, when taken at the same time as this medication, may affect the action of voriconazole or vice versa, voriconazole may affect the action of other medications.
Inform your doctor if you are using the following medications, as simultaneous treatment with voriconazole should be avoided if possible:
Inform your doctor if you are using any of the following medications, as simultaneous treatment with this medication should be avoided as much as possible, and you may need to adjust the dose of voriconazole:
Inform your doctor if you are taking any of the following medications, as you may need to adjust your dose or monitor to ensure that these medications and/or voriconazole continue to produce the desired effect:
Pregnancy and breastfeeding
Do not use voriconazole during pregnancy unless your doctor indicates. Women of childbearing age should use effective contraception. Contact your doctor immediately if you become pregnant during treatment with voriconazole.
Stop breastfeeding before starting to use Voriconazol Teva 200 mg powder for solution for infusion.
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Voriconazole may cause blurred vision or discomfort due to increased sensitivity to light. If this occurs, do not drive or operate tools or machines. Inform your doctor if this occurs.
Voriconazol Teva 200 mg powder for solution for infusion contains hydroxypropyl betadex
This medication contains 2500 mg of cyclodextrin in each vial, which is equivalent to 125 mg / ml when reconstituted in 20 ml.
Do not use in children under 2 years of age unless recommended by your doctor
If you have kidney failure, consult your doctor before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Your doctor will determine the dose based on your weight and the type of infection you have.
Your doctor may change your dose based on your situation.
The recommended dose in adults (including elderly patients) is as follows:
Intravenous route | |
Dose during the first 24 hours(loading dose) | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours (maintenance dose) | 4 mg/kg twice a day |
Your doctor may reduce the dose to 3 mg/kg twice a day depending on your response to treatment.
Your doctor may decide to reduce the dose if you have mild to moderate cirrhosis.
Use in children and adolescents
The recommended dose in children and adolescents is as follows:
Intravenous route | ||
Children aged 2 to less than 12 years and adolescents aged 12 to 14 years weighing less than 50 kg | Adolescents aged 12 to 14 years weighing 50 kg or more; and all adolescents over 14 years | |
Dose during the first 24 hours(loading dose) | 9 mg/kg every 12 hours during the first 24 hours | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours (maintenance dose) | 8 mg/kg twice a day | 4 mg/kg twice a day |
Your doctor may increase or decrease the daily dose depending on your response to treatment.
Voriconazole must be reconstituted and diluted to the correct concentration by hospital pharmacy or nursing staff (for more information, see section 5 and the end of this leaflet).
It will be administered through intravenous infusion (in vein) at a maximum rate of 3 mg/kg per hour for 1 to 3 hours.
If you or your child are taking voriconazole for the prevention of fungal infections, your doctor may stop administering voriconazole if you or your child experience adverse effects related to treatment.
If you forgot a dose of Voriconazole Teva
Given that you will receive this medication under close medical supervision, it is unlikely that you will forget a dose. However, inform your doctor, pharmacist, or nurse if you think you have forgotten a dose.
If you interrupt treatment with Voriconazole Teva
Treatment with voriconazole should be continued for as long as your doctor considers necessary, but the duration of treatment with voriconazole should not exceed 6 months.
Patients with compromised immune systems or those with complicated infections may require longer treatments to prevent the infection from recurring. Once your condition improves, you can substitute intravenous infusion with oral tablets.
When your doctor stops treatment with voriconazole, you should not experience any effects resulting from the interruption.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any occur, they are likely to be mild and temporary. However, some may be serious and require medical attention.
Severe side effects - Stop taking Voriconazol Teva and seek medical attention immediately
Other side effects
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Side effects with unknown frequency (frequency cannot be estimated from available data):
During perfusion, infrequently, there have been reactions withvoriconazol(including redness, fever, sweating, increased heart rate, difficulty breathing, nausea, itching, and skin rash). The doctor may interrupt the perfusion if this happens.
Since it has been observed thatvoriconazolaffects the liver and kidneys, your doctor should monitor liver and renal function through blood tests. Inform your doctor if you have abdominal pain or if your stools have a different consistency.
Cases of skin cancer have been reported in patients treated withvoriconazolfor long periods of time.
The frequency of sunburns or severe skin reactions after exposure to light or the sun was higher in children. If you or your child experience skin problems, your doctor may refer you to a dermatologist who, after consultation, may decide that it is necessary for you or your child to undergo regular follow-up. Elevated liver enzymes were also observed more frequently in children.
If any of these side effects persist or are bothersome, report them to your doctor.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe label orcontainerafter CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25 °C.
Once reconstituted,this medicationmust be used immediately, although, if necessary, it can be stored for up to 24 hours between 2 °C – 8 °C (in a refrigerator).Voriconazole Teva200 mg powder for solution for infusion reconstituted must be diluted first with a compatible infusion diluent before being infused. (For more information see the end of this leaflet).
Medicines should not be disposed of through the drains or in the trash. Dispose of the containers and medicines that you no longer need at the SIGREPoint.If in doubt, ask your pharmacist how to dispose of the containers and medicines that you no longer need. In this way, you will help protect the environment.
Composition of Voriconazole Teva 200 mg powder for solution for infusion
Each vial contains 200 mg of voriconazole, which corresponds to a concentrated solution of 10 mg/ml once reconstituted following the instructions indicated by the pharmacy or nursing staff of the hospital (see the information at the end of this leaflet).
Appearance of the product and contents of the package
Voriconazole Teva 200 mg powder for solution for infusion is presented in a single-use glass vial in the form of a white to off-white powder for solution for infusion.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
TEVA PHARMA, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108 Madrid, Spain
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle-Straße 3, Blaubeuren, 89143
Germany
Or
PLIVA HRVATSKA D.O.O.
Prilaz Baruna Filipovica 25
10000 Zagreb, Croatia
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany | Voriconazole-ratiopharm 200 mg Powder for the preparation of an infusion solution |
Austria | Voriconazole ratiopharm 200 mg Powder for the preparation of an infusion solution |
Belgium | Voriconazole Teva 200 mg powder for solution for infusion |
Cyprus | Voriconazole Teva Pharma 200 mg Κ?νις για δι?λυμα προς ?γχυση |
Croatia | Vorikonazol Pliva200 mg prašak zaotopinu za infuziju |
Denmark | Voriconazole Teva |
Spain | Voriconazole Teva 200 mg powder for solution for perfusion EFG |
France | Voriconazole Teva200 mg, poudre pour solution pour perfusion |
Greece | Voriconazole Teva Pharma 200 mg Κ?νις για δι?λυμα προς ?γχυση |
Hungary | Voriconazole Teva 200 mg por oldatos infúzióhoz |
Italy | Voriconazolo Teva Italia |
Luxembourg | Voriconazole Teva 200 mg poudre pour solution pour perfusion |
Netherlands | Voriconazol Teva 200 mg, poeder voor oplossing voor infusie |
Poland | Voriconazole Teva |
Portugal | Voriconazol Teva 200 mg Pó para solução para perfusão |
United Kingdom | Voriconazole 200 mg powder for solution for infusion |
Czech Republic | Voriconazole Teva 200 mg prášek pro infuzní roztok |
Romania | VORICONAZOL TEVA 200 mg pulbere pentru solutie perfuzabila |
Last review date of this leaflet: July 2024
The detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
-------------------------------------------------------------------------------------------------------------------
The following information is only intended for medical professionals and healthcare professionals:
Information on reconstitution and dilution
Volumes required ofVoriconazole Teva200 mg powder for solution for infusionconcentrate 10 mg/ml
Body weight (kg) | Volumes of Voriconazole Teva 200 mg powder for solution for infusion concentrate (10 mg/ml) required for | ||||
Dose of 3 mg/kg (number of vials) | Dose of 4 mg/kg (number of vials) | Dose of 6 mg/kg (number of vials) | Dose of 8 mg/kg (number of vials) | Dose of 9 mg/kg (number of vials) | |
10 | - | 4.0 ml(1) | - | 8.0 ml(1) | 9.0 ml(1) |
15 | - | 6.0 ml(1) | - | 12.0 ml(1) | 13.5 ml(1) |
20 | - | 8.0 ml(1) | - | 16.0 ml(1) | 18.0 ml(1) |
25 | - | 10.0 ml(1) | - | 20.0 ml(1) | 22.5 ml(2) |
30 | 9.0 ml(1) | 12.0 ml(1) | 18.0 ml(1) | 24.0 ml(2) | 27.0 ml(2) |
35 | 10.5 ml(1) | 14.0 ml(1) | 21.0 ml(2) | 28.0 ml(2) | 31.5 ml(2) |
40 | 12.0 ml(1) | 16.0 ml(1) | 24.0 ml(2) | 32.0 ml(2) | 36.0 ml(2) |
45 | 13.5 ml(1) | 18.0 ml(1) | 27.0 ml(2) | 36.0 ml(2) | 40.5 ml(3) |
50 | 15.0 ml(1) | 20.0 ml(1) | 30.0 ml(2) | 40.0 ml(2) | 45.0 ml(3) |
55 | 16.5 ml(1) | 22.0 ml(2) | 33.0 ml(2) | 44.0 ml(3) | 49.5 ml(3) |
60 | 18.0 ml(1) | 24.0 ml(2) | 36.0 ml(2) | 48.0 ml(3) | 54.0 ml(3) |
65 | 19.5 ml(1) | 26.0 ml(2) | 39.0 ml(2) | 52.0 ml(3) | 58.5 ml(3) |
70 | 21.0 ml(2) | 28.0 ml(2) | 42.0 ml(3) | - | - |
75 | 22.5 ml(2) | 30.0 ml(2) | 45.0 ml(3) | - | - |
80 | 24.0 ml(2) | 32.0 ml(2) | 48.0 ml(3) | - | - |
85 | 25.5 ml(2) | 34.0 ml(2) | 51.0 ml(3) | - | - |
90 | 27.0 ml(2) | 36.0 ml(2) | 54.0 ml(3) | - | - |
95 | 28.5 ml(2) | 38.0 ml(2) | 57.0 ml(3) | - | - |
100 | 30.0 ml(2) | 40.0 ml(2) | 60.0 ml(3) | - | - |
Voriconazoleis a lyophilized sterile product without preservatives of single dose. From a microbiological point of view, the solution must be used immediately once reconstituted. If not used immediately, the time and conditions of conservation before its use are the responsibility of the user, and it must be kept between 2 and 8 ° C (in a refrigerator) for a maximum period of 24 hours.
Compatible infusion solutions:
The reconstituted solution can be diluted with:
Solution for injection of sodium chloride 9 mg/ml (0.9%)
Infusion solution of lactate sodium compound
Solution for infusion of Ringer lactate
Solution for infusion of glucose 5% and Ringer lactate
Solution for infusion of glucose 5% and sodium chloride 0.45% for infusion
Solution for infusion of glucose 5% for infusion
Solution for infusion of glucose 5% and potassium chloride 20 mEq for infusion
Solution for infusion of sodium chloride 0.45% for infusion
Solution for infusion of glucose 5% and sodium chloride 0.9% for infusion
The compatibility of voriconazole with other diluents other than those specifically mentioned above (or mentioned below in "Incompatibilities") is unknown.
Incompatibilities:
Voriconazoleshould not be infused through the same route or cannula simultaneously with other drug infusions, including parenteral nutrition (e.g. Aminofusin 10% Plus).
Simultaneous administration of hemoderivatives and infusion of concentrated solutions of electrolytes for a short period should not be performed with the administration ofvoriconazole.
Parenteral nutrition can be administered simultaneously with the administration ofvoriconazole, but not through the same route or cannula.
Voriconazoleshould not be diluted with sodium bicarbonate solution 4.2%.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.